FDA wants longer studies on Diabetes drugs to determine heart risks
An FDA advisory panel said companies should conduct long-term studies on the heart risks associated with diabetes drugs before they are approved.
Currently companies need to show their drug can control blood sugar in order to get approval.
However, last year a study found the diabetes drug Avandia helped blood sugar levels but possibly increased a patient's risk for heart disease.
The advisory panel said studies looking at heart risks and benefits should start before a drug is approved.
However, they didn't say a drug needed to show a heart benefit.
The F-D-A does not need to follow the panel's recommendation, but they usually do.
Heart disease is a leading cause of death among people with diabetes.